Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

World leaders are dismantling global health programs and cutting back foreign aid. Will an extraordinary new medicine be able ...

In Philadelphia, the leading causes of death are heart disease, cancer, and unintentional drug overdose. While some of these ...

The same tools that companies use to sell products can be used to encourage people to get vaccinated, get a colonoscopy or ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

Elevated immune and neuronal injury markers in MSM with HIV and PrEP suggest lifestyle factors, beyond HIV, drive persistent ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo (lenacapavir), a new era of HIV prevention has dawned. | The FDA signed off ...

HIV-1 negative study participants (median age, 21 years; 99.9% Black) were randomly assigned 2:2:1 to receive twice-yearly subcutaneous lenacapavir (n=2134), once daily Descovy (emtricitabine and ...

In PrEP, patients regularly take one pill every day. There is also an event-driven PrEP, where patients take two pills of PrEP between two and 24 hours before they anticipate having sex. But it's ...

Yeztugo demonstrated superiority over Truvada in reducing the risk of incident HIV-1 infections. The Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir) for pre-exposure ...